<DOC>
	<DOCNO>NCT00715169</DOCNO>
	<brief_summary>This study , randomize , double-blind , placebo-controlled phase 2a trial evaluate potential MLN1202 reduce circulate level C-reactive protein ( CRP ) patient risk factor Atherosclerotic cardiovascular disease ( ASCVD ) . Patients risk factor ASCVD screen inclusion exclusion criterion include assessment C-reactive protein . If patient 's CRP great 3.0 mg/L repeat measurement least 2 week apart , patient enrol , stratify screen CRP level ( ≤5.0 mg/L &gt; 5.0 mg/L ) , randomize receive 1 dose either placebo MLN1202 . Safety assess vital sign , physical examination , clinical laboratory baseline , adverse event ( AE ) report Day 1 Day 113 trial .</brief_summary>
	<brief_title>Double-Blind , Randomized , Placebo-Controlled Trial MLN1202 C-Reactive Protein Levels Patients With Risk Factors Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female age 35 year old Willing able comply protocol duration study Willing use adequate doublebarrier contraceptive method duration study Presence 2 follow risk factor ASCVD : Age 45 year ( male ) 55 year ( female ) great History current cigarette smoking ≥20 pack year History hypertension Body mass index ( BMI ) define weight ( kg ) divide height ( m2 ) ≥30 History hypercholesterolemia define fast lowdensity lipoprotein &gt; 130 mg/dL History highdensity lipoprotein level 40 mg/dL less Diabetes mellitus Family history definable ASCVD event ( myocardial infarction intervention ) firstdegree relative prior age 55 ( male ) 65 ( female ) Patients hypercholesterolemia may stable dos lipidlowering agent change regimen/dose within 60 day prior randomization Have highsensitivity Creactive protein ( peripheral blood ) level &gt; 3.0 mg/L 1 test date separate least 2 week last 12 month ; recent hsCRP must measure Screening within 14 day randomization History stroke History acute coronary syndrome ( ACS ) include unstable angina , acute myocardial infarction ( ST segment elevation nonST segment elevation ) stable angina Evidence coronary artery disease determine either prior history CADrelated event ( stable angina , unstable angina , MI ) evidence diagnostic procedure ( exercise stress test , echocardiogram , stress test , radionucleotide stress test , others ) opinion investigator consistent CAD Diagnosis congestive heart failure clinical evidence suggest CHF include history orthopnea , exertional dyspnea , pedal edema , pulmonary rale , hepatosplenomegaly , cardiomegaly , prediastolic ( S3 ) gallop Uncontrolled hypertension blood pressure &gt; 140/90 Screening Concurrent chronic inflammatory illness ( eg , inflammatory bowel disease , rheumatoid arthritis , chronic obstructive pulmonary disease , asthma , systemic lupus erythematosus ) concurrent chronic infectious illness ( eg , human immunodeficiency virus , tuberculosis , hepatitis , osteomyelitis ) Concurrent use antiinflammatory diseasemodifying agent ( eg , methotrexate , azathioprine , oral corticosteroid ) . Past use ( &gt; 3 month ) antiinflammatory ordisease modify agent acceptable . Aspirin , clopidogrel , nonsteroidal antiinflammatory drug acceptable History cancer exception cervical carcinomainsitu basal cell carcinoma skin within last 5 year History receive live attenuate vaccine within last 60 day prior randomization Use investigational product last 60 day prior randomization History illicit drug use alcohol abuse last year History plan percutaneous coronary intervention , angioplasty coronary stent placement , coronary artery bypass graft vascular surgery plan within study duration Chest Xray within 6 month prior study entry clinically significant finding , opinion investigator Screening electrocardiogram obtain Screening Days 14 1 clinically significant finding , opinion investigator Renal function reflect serum creatinine ≥1.5 time upper limit normal Hepatic function reflect elevated liver function test ( eg , aspartate aminotransferase , alanine aminotransferase total bilirubin ) ≥2 time ULN If female , positive result serum pregnancy test breastfeed Any reason opinion investigator subject enrol study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>